INCY
Adding Incyte to my Special Report: 10 Best Buys for after the Bear–and to my Volatility Portfolio
The Biotech sector is a prototypical risk on/risk off asset class. Just look at the performance of Incyte if you'd like an example. The stock plunged to a low of $58.58 on December 24as investors and traders shunned risk--risk of a recession, risk of the U.S.-China...
What a difference a week makes for biotech stocks
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday's close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big drug...
Incyte knocking on the door of a new upward trend after today’s 6% pop
Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte's (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte's Jakafi in combination with...
Incyte news continues to rebuild credibility of pipeline
Shares of Incyte  (INCY) climbed 2.51% today on the announcement of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer. The company presented the data at...
Selling Incyte calls at $95 now to re-buy after weekend at lower strike
Shares of Incyte (INCY), a member of my Jubak Picks portfolio, have been marching steadily higher in the last couple of weeks. The stock is 19.6% higher since the $61.75 low on August 6. And it's up another 2.06% today, Tuesday, August 28. But the call options I own...
Incyte beats on revenue, misses on earnings; reports good progress in pipeline
I am on vacation until August 26. I am using that downtime to catch up on some of the earnings reports I missed during the very busy second quarter earnings season. On July 30 Incyte (INCY) reported second quarter earnings of 26 cents a share, 4 cents below the Wall...
FDA delivers less than half a loaf to INCY and LLY in approving Olumiant
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...
FDA sets next date for Incyte arthritis drug, baricitinib
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis
Holding Incyte in my Jubak Picks portfolio for mid-year catalysts
When I sold Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio on March 5, one reason I gave was that the catalysts for this biotech were too far out--results from critical drug trials weren't likely to be reported for two years. The reason to hold onto...
A reminder today of why Jubak Pick Incyte has been so weak lately
Today MacroGenics (MGNX) announced that it had closed on its previously announced (October 25) Â license agreement with Incyte (INCY). For an upfront payment of $150 million and up to $420 million in milestone payments Incyte gained the exclusive global rights to...
Time to buy Incyte on the biotech dip
Maybe you didn't even know there was a biotech dip. If all you've been following in the sector is a stock like Nektar Therapeutics (NKTR), a Jubak Picks member (and the call options are a holding in my Volatility Portfolio), you're likely to respond "What dip?" Nektar...Jim’s Stock Alerts
Download Jim’s eBook for Free
